Cardiff Oncology, Inc. (CRDF)
CRDF moved a median of +0.39% 30 minutes after news, and 0.00% by the close. How CRDF actually reacts to news — the realized, point-in-time move the market made, measured across 186 labeled events over the last three years with zero look-ahead.
CRDF’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 47% | 185 |
| 30-min | +0.39% | 53% | 186 |
| 60-min | +0.62% | 54% | 186 |
| to close | 0.00% | 44% | 185 |
| Middle 50% of CRDF reactions | -2.37% to +2.61% |
|---|---|
| Median reaction (30-min) | +0.39% |
| Measured reactions | 186 |
Half of all Cardiff Oncology, Inc. news events land between -2.37% and +2.61% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CRDF reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 14 | -0.86% | 21% | -2.67% |
| Coverage initiations | 12 | +0.32% | 58% | +1.59% |
| Rating reiterations | 14 | -0.78% | 36% | +0.84% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how CRDF ranks against every other measured name →
That’s how CRDF usually reacts — get an email when it moves on news →Email me when CRDF moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CRDF's baseline. Nothing else.
Recent CRDF events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement | Press release | GlobeNewswire | +1.63% | +6.50% | |
| Form 8-K Cardiff Oncology, Inc. For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | +1.63% | +6.50% | |
| Cardiff Oncology to Participate in September 2026 Conferences | Press release | GlobeNewswire | -0.48% | +1.92% | |
| Form DEF 14A Cardiff Oncology, Inc. For: Aug 26 | SEC filing · Form DEF | SEC EDGAR | +0.01% | +0.62% | |
| Form DEFA14A Cardiff Oncology, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.01% | +0.62% | |
| Form PRE 14A Cardiff Oncology, Inc. For: Aug 14 | SEC filing · Form PRE | SEC EDGAR | -2.10% | -4.81% | |
| Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update | Press release | GlobeNewswire | -0.05% | -0.95% | |
| Form 10-Q Cardiff Oncology, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.05% | -0.95% | |
| Form 8-K Cardiff Oncology, Inc. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -0.05% | -0.95% | |
| Form S-8 Cardiff Oncology, Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.37% | +0.24% | |
| Form 8-K Cardiff Oncology, Inc. For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | -1.05% | -1.66% | |
| Cardiff Oncology Announces $10 Million Registered Direct Offering | Press release | GlobeNewswire | -3.26% | -3.34% | |
| Form 8-K Cardiff Oncology, Inc. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -4.35% | |
| Form 8-K Cardiff Oncology, Inc. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | -4.01% | -6.67% | |
| Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting | Press release | GlobeNewswire | +2.03% | +2.03% | |
| Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +2.03% | +2.03% | |
| Form 8-K Cardiff Oncology, Inc. For: May 27 | SEC filing · Form 8-K | SEC EDGAR | -12.00% | -15.43% | |
| Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC | Press release | GlobeNewswire | -0.55% | -1.66% | |
| Form 8-K Cardiff Oncology, Inc. For: May 19 | SEC filing · Form 8-K | SEC EDGAR | +3.49% | +6.98% | |
| Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update | Press release | GlobeNewswire | +1.51% | +1.21% | |
| Form 10-Q Cardiff Oncology, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.51% | +1.21% | |
| Form 8-K Cardiff Oncology, Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +1.51% | +1.21% | |
| Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -4.05% | -6.36% | |
| Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity | Press release | GlobeNewswire | +0.58% | +0.00% | |
| Form ARS Cardiff Oncology, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.48% | +1.77% | |
| Form DEF 14A Cardiff Oncology, Inc. For: Jun 11 | SEC filing · Form DEF | SEC EDGAR | -1.48% | +1.77% | |
| Form DEFA14A Cardiff Oncology, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -1.48% | +1.77% | |
| Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026 | Press release | GlobeNewswire | -0.05% | -4.06% | |
| Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting | Press release | GlobeNewswire | +0.56% | +0.56% | |
| Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth | Press release | GlobeNewswire | -0.31% | -3.07% | |
| Form 8-K Cardiff Oncology, Inc. For: Apr 06 | SEC filing · Form 8-K | SEC EDGAR | -0.31% | -3.07% | |
| Form 8-K Cardiff Oncology, Inc. For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | +2.85% | +0.00% | |
| Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting | Press release | GlobeNewswire | -2.78% | +1.11% | |
| Cardiff Oncology to Participate in Three Upcoming Investor Conferences | Press release | GlobeNewswire | +1.79% | -0.51% | |
| Form 8-K Cardiff Oncology, Inc. For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | +4.54% | +8.52% | |
| Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update | Press release | GlobeNewswire | +4.54% | +8.52% | |
| Form 10-K Cardiff Oncology, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +4.54% | +8.52% | |
| Form 8-K Cardiff Oncology, Inc. For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | +4.54% | +8.52% | |
| Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference | Press release | GlobeNewswire | +0.00% | +4.49% | |
| Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development | Press release | GlobeNewswire | -8.61% | -4.31% | |
| Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC | Press release | GlobeNewswire | -8.61% | -4.31% | |
| Form 8-K Cardiff Oncology, Inc. For: Jan 27 | SEC filing · Form 8-K | SEC EDGAR | -0.58% | -18.59% | |
| Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025 | Press release | GlobeNewswire | -0.18% | +5.24% | |
| Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference | Press release | GlobeNewswire | +1.17% | +9.35% | |
| Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference | Press release | GlobeNewswire | +1.48% | +2.46% | |
| Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update | Press release | GlobeNewswire | +1.60% | +0.00% | |
| Form 10-Q Cardiff Oncology, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.60% | +0.00% | |
| Form 8-K Cardiff Oncology, Inc. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +1.60% | +0.00% | |
| Cardiff Oncology to Participate in Two Upcoming Investor Conferences | Press release | GlobeNewswire | +1.36% | +1.36% | |
| Cardiff Oncology to Participate in Two Upcoming Investor Conferences | Press release | GlobeNewswire | -0.24% | +3.30% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CRDF section they belong to.
Where else CRDF is measured.
CRDF earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Cardiff Oncology, Inc.'s median reaction calculated?
Every labeled CRDF news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 186 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 53% of CRDF's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CRDF's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.